154 related articles for article (PubMed ID: 8339212)
1. Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders.
Baron BW; Mick R; Baron JM
Cancer; 1993 Aug; 72(4):1209-18. PubMed ID: 8339212
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic plateletpheresis in a case of symptomatic thrombocytosis in chronic myeloid leukemia.
Thakral B; Saluja K; Malhotra P; Sharma RR; Marwaha N; Varma S
Ther Apher Dial; 2004 Dec; 8(6):497-9. PubMed ID: 15663550
[TBL] [Abstract][Full Text] [Related]
3. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.
Boddu P; Falchi L; Hosing C; Newberry K; Bose P; Verstovsek S
Leuk Res; 2017 Jul; 58():14-22. PubMed ID: 28380402
[TBL] [Abstract][Full Text] [Related]
4. Long-term plateletpheresis in the management of primary thrombocytosis.
Goldfinger D; Thompson R; Lowe C; Kurz L; Belkin G
Transfusion; 1979; 19(3):336-8. PubMed ID: 452073
[TBL] [Abstract][Full Text] [Related]
5. Primary thrombocythemia: a current perspective.
Mughal TI
Stem Cells; 1995 Jul; 13(4):355-9. PubMed ID: 7549894
[TBL] [Abstract][Full Text] [Related]
6. Improvement of platelet function following plateletpheresis in patients with myeloproliferative diseases.
Orlin JB; Berkman EM
Transfusion; 1980; 20(5):540-5. PubMed ID: 7423594
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.
Rushing D; Goldman A; Gibbs G; Howe R; Kennedy BJ
Am J Clin Oncol; 1982 Jun; 5(3):307-13. PubMed ID: 6952759
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and side effects of hydroxyurea used for primary thrombocythemia.
Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F
Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962
[TBL] [Abstract][Full Text] [Related]
10. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia.
Bolin RW; Robinson WA; Sutherland J; Hamman RF
Cancer; 1982 Nov; 50(9):1683-6. PubMed ID: 6956430
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic plateletpheresis in thombocythemia.
Panlilio AL; Reiss RF
Transfusion; 1979; 19(2):147-52. PubMed ID: 432925
[TBL] [Abstract][Full Text] [Related]
12. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.
Verner E; Forsyth C; Grigg A
Leuk Lymphoma; 2014 May; 55(5):1139-43. PubMed ID: 23879199
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
[TBL] [Abstract][Full Text] [Related]
14. Anagrelide: 20 years later.
Emadi A; Spivak JL
Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
[TBL] [Abstract][Full Text] [Related]
15. The role of blood component removal in essential and reactive thrombocytosis.
Greist A
Ther Apher; 2002 Feb; 6(1):36-44. PubMed ID: 11886575
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
Schwartz JH; Cannellos GP
Blood; 1975 Jul; 46(1):11-6. PubMed ID: 1055610
[TBL] [Abstract][Full Text] [Related]
17. Control of thrombocytosis by plateletpheresis using a cell separator.
Beard ME; Blacklock HA; Varcoe AR
N Z Med J; 1980 Feb; 91(654):136-8. PubMed ID: 6929973
[TBL] [Abstract][Full Text] [Related]
18. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytosis associated with a myeloproliferative disorder in a dog.
Degen MA; Feldman BF; Turrel JM; Goding B; Kitchell B; Mandell CP
J Am Vet Med Assoc; 1989 May; 194(10):1457-9. PubMed ID: 2722642
[TBL] [Abstract][Full Text] [Related]
20. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
